TriangleAndrogen Deprivation Therapy (ADT) (NCT07801664)
Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT07801664). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for men aged 18 or older with high-risk prostate cancer, low or intermediate ARTERA scores, and no lymph-node or distant spread.
The idea: six months of hormone therapy lowers testosterone, alongside intensified radiation to the prostate and nearby nodes. Radiation uses stereotactic treatment, with or without an internal radiation boost. Researchers track distant spread over five years. Prior hormone treatment cannot exceed three months.
This phase 2 study plans 90 patients. Michael Zelefsky leads at NYU Langone in New York, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.